Bringing Product Innovations to Market: from Non-Surgical Treatment of Cerebral Aneurysms to At-Home Molecular Testing for Covid, Flu and Others

Register in advance for this meeting:
https://ucsd.zoom.us/meeting/register/tJUtf-CpqjgsGd0a2UqSniqtvI2sbNZmQGYp 

Friday, June 5, 2020 -
2:00pm to 3:00pm
Zoom
Erik T. Engelson

President & CEO of Lucira Health, Inc

Board Member at Neptune Medical, DeVoro Medical and ARANZ Medical

Venture Partner with ShangBay Capital

Bringing Product Innovations to Market: from Non-Surgical Treatment of Cerebral Aneurysms to At-Home Molecular Testing for Covid, Flu and Others

Bio: 

Mr. Engelson, is currently President & CEO of Lucira Health, Inc, a board member at Neptune Medical, DeVoro Medical and ARANZ Medical, and is a Venture Partner with ShangBay Capital.  Just prior, he was CEO of Medina Medical, which he sold to Medtronic.  Previous associations include Partner at The Foundry (a venture-funded medical device incubator), CEO of two Foundry companies, CFO of Fluidigm Corporation, and Venture Partner at both Versant Ventures and Institutional Venture Partners.  Earlier, Mr. Engelson spent 13 years in various operating roles at Target Therapeutics where he led the early start-up into the then nascent field of Interventional Neuroradiology (stroke intervention), developed its first products, helped take the company public and was its GM following the acquisition by Boston Scientific.  He is the inventor of 50+ medical device patents.  Mr. Engelson holds B.A. and M.S. degrees in Microbiology and Bioengineering from UC San Diego, and an Executive MBA from the Stanford Graduate School of Business.  Mr. Engelson is a Trustee Emeritus of the UC San Diego Foundation, Initial Chairman of the Board of Trustees of UC San Diego’s Bioengineering Department, a member of the UC San Diego Biology Department Dean’s Leadership Committee and an elected fellow of the American Institute for Medical and Biological Engineering (AIMBE).